Loading...
Loading...
CTSO| Name | Value |
|---|---|
| Revenues | 8.1M |
| Cost of Revenue | 3.4M |
| Gross Profit | 4.7M |
| Operating Expense | 11.2M |
| Operating I/L | -6.6M |
| Other Income/Expense | 0.4M |
| Interest Income | 0.0M |
| Pretax | -6.2M |
| Income Tax Expense | -0.4M |
| Net Income/Loss | -6.2M |
Cytosorbents Corporation specializes in the research, development, and commercialization of medical devices utilizing its blood purification technology platform. Its flagship product, CytoSorb, is an extracorporeal cytokine filter used in the treatment of sepsis and other critical care applications, as well as in perioperative complications of cardiopulmonary bypass surgery and organ transplant procedures. The company also offers VetResQ for animal therapy, HemoDefend for blood purification, K+ontrol for severe hyperkalemia, and ContrastSorb for contrast-induced nephropathy risk reduction. Additionally, it is involved in the development of BetaSorb for chronic renal failure, DrugSorb for toxic chemical removal, and DrugSorb-ATR for antithrombotic removal.
